City to roll out plan for 16th Street tech corridor
The city of Indianapolis plans to announce a major initiative to turn a stretch of 16th Street northwest of downtown into a hub for biotechnology and other high-tech companies.
Life Science & Biotech
Articles
Anson Group CEO thrives on helping clients work with FDA
Colleen Hittle became CEO and sole owner of the Indianapolis-based pharmaceutical and medical device consulting firm in April.
Roche wins as high court limits university patent rights
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
Life sciences logistics firm opens new tissue storage facility
BioStorage Technologies’ $4.6 million facility, located near the Indianapolis International Airport, will be used to prepare, store and transport tissue and blood samples.
Brain barrier breached in push to deliver Alzheimer’s drug
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s disease.
Lilly licenses Xigris rights to new biotech firm
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
Zimmer faces new threat to dominance
Warsaw-based Zimmer Holdings Inc. has enjoyed eight years as the giant in the industry of selling knee- and hip-replacement implants to hospitals. But now it faces a challenge from Johnson & Johnson.
BISHOP: Warsaw’s orthopedics whizzes will master biologics
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration, too.
Endocyte’s potential enthralls investors
Shares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common wisdom is it won’t see sales from its first cancer drug until 2014.
Indianapolis bio sector hopeful as venture firms cash out
Profits flowing from earlier investments could mean more available capital, but firms continue to be selective in placing their bets.
Zimmer Holdings quarterly profit rises 2 percent
Warsaw-based orthopedic implant maker Zimmer Holdings Inc. said Thursday its first-quarter profit rose 2 percent on higher sales of reconstructive, dental and other products.
Dow AgroSciences reports record revenue
Indianapolis-based Dow AgroSciences on Thursday reported sales of $1.6 billion in its first quarter, up 17 percent from the same period last year due to higher volume and increased prices.
Life sciences firm Hycor moving HQ, jobs to central Indiana
California-based Hycor Biomedical Inc. plans to move its headquarters to central Indiana, creating as many as 20 jobs in the next two years, state economic development officials announced Wednesday morning.
Roche wins approval of HPV test
Roche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market for automated cervical cancer tests.
Much unknown about new Cook Group CEO
Carl Cook has been tabbed to replace his father, Bill Cook, who died a week ago. But many in the Bloomington business community know little about him, which reflects the company’s strict privacy policy.
FDA wants further testing of Lilly pancreas drug
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
Lilly’s Bydureon wins backing of European drug panel
The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
China making big gains in drug R&D jobs state covets
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
Wishard gives IT firms in health and life sciences a place to test products
TechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
Tax breaks approved for bioanalytical lab operator
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.’s request for a tax abatement to build a laboratory at Purdue Research Park in Indianapolis.